Robert E. Dudley, Ph.D., has served as our Chief Executive Officer, President and Chairman of our board of directors since Clarus's inception in February 2004. Prior to that, from 2001 to 2003, he served as President, Chief Executive Officer, and Director of Anagen Therapeutics, Inc., a private biopharmaceutical company affiliated with the University of Chicago. He served as President, Chief Executive Officer, and Director of Unimed Pharmaceuticals, Inc. from 1999 to 2001 during which time Unimed received FDA approval for and launched AndroGel (which he co-invented). From 1994 to 2001, Dr. Dudley held several senior level executive positions at Unimed Pharmaceuticals, Inc., a public company acquired by Solvay Pharmaceuticals in 1999. Dr. Dudley has over 25 years of experience in the field of testosterone replacement therapy, has published numerous articles in peer-reviewed medical journals, and is an inventor on several testosterone-related patents – including those patents that cover Clarus' oral TU formulations.
Dr. Dudley received his B.S. in Biology from Pepperdine University, Seaver College, his M.S. in Biology from University of New Mexico, and his Ph.D., with honors, in Pharmacology and Toxicology from the University of Kansas School of Medicine. Dr. Dudley is also a board-certified toxicologist.
James is a co-founder of Thomas, McNerney & Partners and has been investing in health care companies since 1992. James previously headed Warburg Pincus LLC's medical technology private equity practice, where he had responsibility for investments in biotechnology, pharmaceutical, medical device and diagnostic companies. Prior to joining Warburg, James was a Vice President at Goldman Sachs International in London. He is currently a board member of CAS Medical Systems, Inc. (CASM), Clarus Therapeutics, Inc., Galil Medical Ltd., Keystone Dental, Inc. and Torax Medical, Inc. Historical investments include: American Medical Systems Holdings, Inc. (AMMD), Coley Pharmaceutical Group, Inc. (COLY sold to Pfizer), The Medicines Company (MDCO), NeXagen, Inc. (NXGN/NXTR sold to Gilead Sciences, Inc.), OsteoBiologics, Inc. (sold to Smith & Nephew plc), Oxford GlycoSciences, plc (OGSI sold to Celltech Group plc), Transkaryotic Therapies, Inc. (TKTX sold to Shire Pharmaceuticals Group plc), Visible Genetics, Inc. (VGIN sold to Bayer Corporation), Wright Medical Group, Inc. (WMGI), and Xomed Surgical Products, Inc. (XOMD sold to Medtronic, Inc.). James graduated magna cum laude a B.S. in Economics from the Wharton School at the University of Pennsylvania and received an M.Sc. in Economics from the London School of Economics.
Alex joined H.I.G. BioHealth Partners as a Managing Director in January 2016. He currently serves on the board of directors for Clarus Therapeutics and Keystone Dental. Prior to H.I.G., Alex spent 13 years at Thomas, McNerney & Partners. Previous board seats included Auspex Pharmaceuticals (sold to Teva), InnoPharma (sold to Pfizer), Quinnova (sold to Amneal), Celator (public), Zogenix (public), Tranzyme (merged with Ocera) and observer roles at PCI Pharma Services and Coley Pharmaceutical (sold to Pfizer). Prior to Thomas, McNerney, Alex spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan). Alex is the co-chair of the Business Advisory Council of the Children's Tumor Foundation, an advisor for the Partnership Fund of NYC, which manages a bioaccelarator to advance local healthcare research, and is on the Life Sciences Council for Springboard Enterprises, a group that assists women entrepreneurs. He is also a board member for the Greenwich Council of the Boy Scouts of America. He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.
Bruce C. Robertson, Ph.D., has served as a member of our board of directors since November 2007. Since 2005, he has served as a Managing Director at H.I.G. BioHealth Partners, the dedicated healthcare affiliate of H.I.G. Capital, the leading private equity firm in the lower middle market, with $19 billion under management. He previously served as a Managing Director at Toucan Capital, a healthcare-focused venture capital firm. Dr. Robertson also serves on the board of directors of a number of private companies and organizations, including Iconic Therapeutics, CardioFocus, Inc., Apollo Endosurgery, and Adventist Healthcare. Dr. Robertson received a B.S.E. in Chemical/Biomedical Engineering from the University of Pennsylvania, an M.B.A. from Harvard Business School and a Ph.D. from the University of Delaware.
Karen Hong, Ph.D., has served as a member of our board of directors since September 2011. Dr. Hong is Managing Director of Parkside Place LLC, a life science advisory firm. Formerly, she was a Partner at ProQuest Investments, a healthcare dedicated venture fund. Dr. Hong joined ProQuest in 2001 as an Associate, became a Principal in 2004, and became a Partner in 2013. Currently, Dr. Hong serves on the Board of Directors of Agile Therapeutics (Nasdaq: AGRX). In addition, she has represented ProQuest as an observer on the Board of Directors of BioRexis Pharmaceutical Corp. (acquired by Pfizer), Gloucester Pharmaceuticals (acquired by Celgene) and LEAD Therapeutics (acquired by BioMarin), among others. She brings over twenty years of experience in life science investing and biomedical research. Prior to joining ProQuest, Dr. Hong provided technical consultation to the healthcare group at BancBoston Ventures and pursued academic research in molecular biology and chemistry. She led numerous research projects in the area of mammalian cancer genetics and genomics in the laboratory of Dr. Eric Lander at the Whitehead Institute for Biomedical Research and authored several publications in leading scientific journals. Dr. Hong received a B.S. in chemistry and a B.A. in molecular biology from the University of California at Berkeley, where she graduated with honors and as a member of Phi Beta Kappa. She received a Ph.D. in biology from the Massachusetts Institute of Technology.
Mengjiao Jiang has served as a member of our board of directors since May 2014. Since December 2013, she has served as Partner of C-Bridge Capital Partners LLC, a China-based investment management firm focused on healthcare investments, which she co-founded. Prior to that, Ms. Jiang served from March 2012 to December 2013 as Chief Operating Officer and Director in the Principal Investments Group of Far East Horizon Ltd., a leasing company in China. Ms. Jiang previously was Managing Director at the Shanghai-based investment manager, ARC China, where she established its China operations, from March 2008 to June 2012. Ms. Jiang received a B.A. in economics and political science from Wellesley College.
Elizabeth A. Cermak has served as a member of our board of directors since July 2014. Ms. Cermak also serves as a Board Member for SteadyMed Therapeutics. Most recently, Ms. Cermak was Executive Vice President, Chief Commercial Officer and member of the Executive Committee of POZEN, Inc. Prior to that, Ms. Cermak served as the Worldwide Vice President of Global Marketing for Personal Products, a segment of the Johnson & Johnson Consumer Health Care business, and also served as the Vice President of the Women's Healthcare RX Franchise for Ortho-McNeil Pharmaceutical. Ms. Cermak received her undergraduate degree from Franklin & Marshall College and an MBA from Drexel University.
Mark A. Prygocki, Sr. has served as a member of our board of directors and Chairman of the audit committee since July 2014. Mr. Prygocki currently serves on the Board of Directors of Revance Therapeutics as well as Chairman of the audit committee. Mr. Prygocki is a pharmaceutical industry leader with over 20 years of experience, specializing in corporate strategy and operational efficiency. He was employed by Medicis Pharmaceutical Corporation for more than 20 years and served as President from July 2010 to December 2012. Prior to that, Mr. Prygocki held several senior‐level positions at Medicis, including Chief Operating Officer, Executive Vice President, and Chief Financial Officer and Treasurer. Mr. Prygocki's previous experience includes work at Citigroup, an investment banking firm, in the regulatory reporting division. Prior to that, Mr. Prygocki spent several years in the audit department of Ernst & Young, LLP. He is certified by the Arizona State Board of Accountancy and the New York Society of CPAs. Mr. Prygocki serves on the board of Whispering Hope Ranch Foundation, a non-profit organization that assists children with special needs.